• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ABCB1 SNP rs4148738 modulation of apixaban interindividual variability.

作者信息

Dimatteo Claudia, D'Andrea Giovanna, Vecchione Gennaro, Paoletti Oriana, Tiscia Giovanni Luca, Santacroce Rosa, Correale Michele, Brunetti Natale, Grandone Elvira, Testa Sophie, Margaglione Maurizio

机构信息

Medical Genetics, Dept. of Clinical and Experimental Medicine, University of Foggia, Italy.

Atherosclerosis and Thrombosis Unit, I.R.C.C.S. "Casa Sollievo della Sofferenza", S. Giovanni Rotondo, Italy.

出版信息

Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005. Epub 2016 Jul 12.

DOI:10.1016/j.thromres.2016.07.005
PMID:27434880
Abstract
摘要

相似文献

1
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability.
Thromb Res. 2016 Sep;145:24-6. doi: 10.1016/j.thromres.2016.07.005. Epub 2016 Jul 12.
2
Apixaban (eliquis) for stroke prevention in atrial fibrillation.
Am Fam Physician. 2014 Apr 15;89(8):672-5.
3
Apixaban in acute coronary syndromes.阿哌沙班在急性冠状动脉综合征中的应用。
Cardiovasc Ther. 2011 Oct;29(5):285-90. doi: 10.1111/j.1755-5922.2010.00195.x. Epub 2010 Jun 11.
4
Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction.阿哌沙班溶解一名陈旧性前间隔心肌梗死患者的心尖血栓。
Anatol J Cardiol. 2015 Aug;15(8):671-2. doi: 10.5152/AnatolJCardiol.2015.6285.
5
Apixaban (Eliquis)--a new oral anticoagulant for atrial fibrillation.阿哌沙班（艾乐妥）——一种用于治疗心房颤动的新型口服抗凝药。
Med Lett Drugs Ther. 2013 Feb 4;55(1409):9-10.
6
Upcoming oral factor Xa inhibitors for venous thromboembolism prophylaxis in patients undergoing major orthopedic surgery: rivaroxaban (Xarelto) and apixaban (Eliquis) review.
Conn Med. 2012 Jan;76(1):39-42.
7
A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.阿哌沙班用于心房颤动卒中预防的综述：来自ARISTOTLE研究的见解
Expert Rev Cardiovasc Ther. 2013 Sep;11(9):1105-14. doi: 10.1586/14779072.2013.824181. Epub 2013 Sep 2.
8
Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.阿哌沙班与依诺肝素用于髋或膝关节置换术后血栓预防：来自ADVANCE-2和ADVANCE-3试验的8464例患者主要静脉血栓栓塞和出血的汇总分析
J Bone Joint Surg Br. 2012 Feb;94(2):257-64. doi: 10.1302/0301-620X.94B2.27850.
9
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.使用网状Meta分析比较达比加群、利伐沙班和阿哌沙班在房颤患者中的疗效和安全性。
Int Angiol. 2012 Aug;31(4):330-9.
10
Apixaban for extended treatment of venous thromboembolism.阿哌沙班用于静脉血栓栓塞症的延长治疗。
N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.

引用本文的文献

1
Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up.在未经抗凝治疗的非瓣膜性心房颤动患者中，利伐沙班治疗相关出血事件：一项基于基因角度并随访 INR 的纵向研究。
Medicina (Kaunas). 2024 Oct 18;60(10):1712. doi: 10.3390/medicina60101712.
2
Gene polymorphism as a cause of hemorrhagic complications in patients with non-valvular atrial fibrillation treated with oral vitamin K-independent anticoagulants.基因多态性是口服维生素 K 非依赖性抗凝剂治疗非瓣膜性心房颤动患者出血并发症的原因。
Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241249886. doi: 10.1177/17539447241249886.
3
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.
心血管药物的药物基因组学与动脉粥样硬化血栓形成、血栓栓塞和动脉粥样硬化风险
Genes (Basel). 2023 Nov 9;14(11):2057. doi: 10.3390/genes14112057.
4
Pharmacokinetic and Pharmacogenetic Predictors of Major Bleeding Events in Patients with an Acute Coronary Syndrome and Atrial Fibrillation Receiving Combined Antithrombotic Therapy.急性冠状动脉综合征合并心房颤动患者接受联合抗栓治疗时主要出血事件的药代动力学和药物遗传学预测因素
J Pers Med. 2023 Sep 12;13(9):1371. doi: 10.3390/jpm13091371.
5
Challenges of Anticoagulant Therapy in Atrial Fibrillation-Focus on Gastrointestinal Bleeding.房颤抗凝治疗面临的挑战-关注胃肠道出血。
Int J Mol Sci. 2023 Apr 7;24(8):6879. doi: 10.3390/ijms24086879.
6
Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients.八种药代动力学基因变异与非瓣膜性心房颤动患者使用直接口服抗凝剂后的出血风险无关。
Front Pharmacol. 2022 Nov 24;13:1007113. doi: 10.3389/fphar.2022.1007113. eCollection 2022.
7
Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events.阿哌沙班血浆水平的遗传决定因素及其与出血和血栓栓塞事件的关系。
Front Genet. 2022 Sep 14;13:982955. doi: 10.3389/fgene.2022.982955. eCollection 2022.
8
Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants.直接口服抗凝剂治疗患者的基因多态性与出血之间的关联
Pharmaceutics. 2022 Sep 7;14(9):1889. doi: 10.3390/pharmaceutics14091889.
9
Pharmacogenomics Informs Cardiovascular Pharmacotherapy.药物基因组学指导心血管药物治疗。
Methods Mol Biol. 2022;2547:201-240. doi: 10.1007/978-1-0716-2573-6_9.
10
Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation.阿哌沙班血浆水平与出血有关吗？非瓣膜性心房颤动患者出血的临床结局及预测因素。
Biomedicines. 2022 Aug 18;10(8):2001. doi: 10.3390/biomedicines10082001.